Navigation Links
Mylan and Pfizer Announce Epinephrine Auto-injector Settlement Agreement
Date:2/16/2012

e settlement; strategies by competitors or other third parties to delay or prevent product introductions; risks inherent in legal and regulatory processes; and the other risks detailed in the company's periodic filings with the Securities and Exchange Commission. The company undertakes no obligation to update these statements for revisions or changes after the date of this release.

PFIZER DISCLOSURE NOTICE: The information contained in this release is of February 16, 2012. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information that involves substantial risks and uncertainties regarding the settlement agreement and the marketing of the EpiPen Auto-Injector. Actual results may differ materially from those expressed in or implied by such forward-looking statements. Such risks and uncertainties include, among other things, the possibility of legal or regulatory challenges to the settlement agreement and the impact of competitive pressures on the marketing of the EpiPen Auto-Injector.

A further list and description of risks and uncertainties can be found in Pfizer's Annual Report on Form 10-K for the fiscal year ended December 31, 2010 and in its reports on Form 10-Q and Form 8.


 


'/>"/>
SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Mylan to Change Name of Specialty Subsidiary From Dey Pharma to Mylan Specialty
2. Mylan Actively Addressing Shortage of Preservative-Free Methotrexate Injection
3. Mylan CEO Heather Bresch Testifies Before Congress in Support of Generic Drug User Fee Program and Urges Update of Federal Food, Drug and Cosmetic Act of 1938 to Create a Level Playing Field for Manufacturers
4. Mylan Completes Acquisition of Two Limited-Competition Dermatological Products from Valeant
5. Valeant Pharmaceuticals Completes Divestiture of Generic Dermatology Products to Mylan
6. Mylan Receives Tentative FDA Approval for Generic Version of Lipitor®
7. Mylan to Host Investor Day on Feb. 21, 2012, in New York City
8. Mylan Launches Innovative Version of Antiepileptic Drug Levetiracetam
9. Mylan Launches First Generic Version of Teveten® Tablets
10. Mylan Receives Approval for First-to-File Generic Keppra XR® Extended-Release Tablets
11. Mylan Receives WHO Approval for Innovative Second-Line-in-a-Box HIV/AIDS Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2015)... 20, 2015 Merrimack Pharmaceuticals, Inc. (Nasdaq: ... for the Phase 1 study of MM-302, a ... cancer.  The results were presented today by Patricia ... session at the 2015 American Association for Cancer ... PA. Data described the safety and ...
(Date:4/20/2015)... April 20, 2015  Sigma-Aldrich Corporation (Nasdaq: ... (CR) Magazine,s list of the 100 Best Corporate ... corporate responsibility performance.  Sigma-Aldrich ranked fifth, its highest ... the list. "We are honored to ... efforts and we are extremely pleased with our ...
(Date:4/20/2015)... April 20, 2015 The preclinical contract research organization ... of drugs and safety testing of medical devices, announces that ... this week,s workshop " Drug Transporters in ADME: From the ... . The title of Dr. Hidalgo,s talk is "Modern ... session entitled "Transporter Tools of the Future." The ...
Breaking Medicine Technology:Merrimack Announces Final Clinical Results for MM-302 Phase 1 Study Demonstrating Robust Activity in Heavily Pre-Treated Patients with HER2-Positive Metastatic Breast Cancer 2Merrimack Announces Final Clinical Results for MM-302 Phase 1 Study Demonstrating Robust Activity in Heavily Pre-Treated Patients with HER2-Positive Metastatic Breast Cancer 3Merrimack Announces Final Clinical Results for MM-302 Phase 1 Study Demonstrating Robust Activity in Heavily Pre-Treated Patients with HER2-Positive Metastatic Breast Cancer 4Merrimack Announces Final Clinical Results for MM-302 Phase 1 Study Demonstrating Robust Activity in Heavily Pre-Treated Patients with HER2-Positive Metastatic Breast Cancer 5Sigma-Aldrich Named to CR Magazine's 100 Best Corporate Citizens List 2Absorption Systems Chief Scientist Ismael Hidalgo to Present at International Workshop on Drug Transporters 2
... YORK, Oct. 7, 2011 Intellect Neurosciences, Inc. (OTCBB: ... clinical-stage pipeline, and multiple licenses with major pharmaceutical companies ... interview with Dr. Daniel Chain, Ph.D., Chairman and CEO ... Dr. Chain will be discussing the state ...
... Health Solutions, Inc. (NYSE: MHS ) today ... the Silver Award for Best Practices in Health Care ... healthcare accreditation organization, during the URAC 12th Annual Quality ... ) Medco,s program was selected as one ...
Cached Medicine Technology:Intellect Neurosciences CEO to be Featured on Wall Street Reporter 2Medco Wins 2011 URAC Award for Best Practices in Health Care Consumer Empowerment and Protection 2Medco Wins 2011 URAC Award for Best Practices in Health Care Consumer Empowerment and Protection 3
(Date:4/21/2015)... 2015 CALNOC, the nation’s first nursing ... RN, FAAN, will keynote their upcoming conference – Navigating ... CA on October 26, 2015. , Dr. Burnes ... of Nurse Executives (AONE) and the first African American ... American Academy of Nursing and the National Black Nurses ...
(Date:4/21/2015)... VA (PRWEB) April 21, 2015 The Science ... as a special addition to its Lunch Break Science program. ... World of Quarks! – taking guests from the subatomic world ... form. , The Museum invites members of the community to ... the Jefferson Lab physicist. Guests will delve into the nucleus ...
(Date:4/21/2015)... (PRWEB) April 21, 2015 Renewable energy, ... a few of the Earth Day topics USM ... and national leaders debate the affect of climate change ... variety of subject matter touching on the environmental concerns ... segments will delve into sustainable lifestyles, clean air options, ...
(Date:4/21/2015)... April 21, 2015 On Saturday, May ... the rest of his team from Georgia Eye ... to End Lupus Now, being held in Piedmont Park ... Walk proved to be the largest LFA-sponsored walk in ... effort to raise funds and awareness for lupus, an ...
(Date:4/21/2015)... 21, 2015 Invictus Medical has ... Illinois university for a second innovative technology aimed ... conducive to newborn infants’ cognitive development. , “This ... problems we have identified through extensive interviews and ... George Hutchinson, Invictus Medical’s Chief Technology Officer. “We ...
Breaking Medicine News(10 mins):Health News:Nationally Recognized Nurse Leader Linda Burnes Bolton to Present Keynote Address at CALNOC Conference 2Health News:Quarks and Forks at the Science Museum of Virginia 2Health News:USM Studios’ Programming Focuses on the Environment 2Health News:9th Annual Walk to End Lupus Now 2Health News:9th Annual Walk to End Lupus Now 3Health News:Invictus Medical Secures Rights to Second Promising New NICU Technology 2
... Drug Administration is scrutinizing the claims made by a ... to the claims made by the businessman Allan Lord, he ... The Bio-Germ Protection kits contain skin lotion, a nasal spray, ... online. ,According to the company, the lotion, which is ...
... 'Transcranial Magnetic Stimulation' (TMS) maybe the way forward ... aggressive electro-shock therapy., ,Electro-Shock Therapy or ECT is ... treat severe depression for many decades. However, it can ... and requires general anesthesia. In ECT the doctors pass ...
... can prevent the spread of melanoma// and other forms of ... a chemical found in turmeric, can block a biological pathway ... The chemical in the spices inhibits a protein called nuclear ... abnormal inflammations that can lead to a number of disorders ...
... revealed that consumption of fruits, vegetables and foods high in ... risk of heart disease. ,Western cuisines are not so ... plant foods in the diet. ,10 healthy individuals were ... to each of them. The diets were a vegetarian diet ...
... be responsible for various immune deficiency syndromes, and researchers// ... two different form of immune deficiency conditions called immunoglobulin ... ,Immune deficiency syndrome may be hereditary or acquired. Hereditary ... defects in the cells and tissues that are responsible ...
... help in the brain development of foetus and infants for ... administered to pregnant women. A new study conducted by scientists ... slow down the cognitive decline in middle-aged subjects. , ... and women) with increased levels of homocysteine. This amino acid ...
Cached Medicine News:Health News:A New Product Offering protection against anthrax 2Health News:Strong Magnetic Stimulation Can Help Treating Severe Depression 2Health News:Fibre Rich Food A Boon For Lowering Cholesterol 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: